本刊讯(记者李晓雅)2009年11月26日,第62届全国药品交易会在成都盛大开幕,中国版甲流药物奥尔菲(达菲)、石家庄四药研发的国家二类抗病毒新药恩尔欣胶囊等产品受到极大关注。由我集团《医药经理人》杂志承办的“中国药业60年·60人”发榜活动,成了本届药交会的一大亮点。更令人振奋的是,作为首家在美国纽约证券交易所上市的中国化学生物制药企业先 (Reporter Li Xiaoya) On November 26, 2009, the 62nd session of the National Pharmaceutical Fair opened grandly in Chengdu. The Chinese version of the A flu drug Orffi (Tamiflu), Shijiazhuang four drugs developed by the national second-class antiviral drugs En Er Xin capsules and other products have received great attention. Organized by the Group “Medical Manager” magazine, “60 Years of Chinese Pharmaceutical Industry and 60 People” list activities, has become a major highlight of this year’s drug trade association. Even more exciting is that as the first listed on the New York Stock Exchange, the Chinese chemical biopharmaceutical companies